Shaperon

2008

2016

Received approval from the Korean Ministry of Food and Drug Safety (MFDS) for Phase 1 clinical trial of an atopic dermatitis treatment.

2018

2019

Initiated Phase 1 clinical trial of NuSepin for sepsis.
Alzheimer’s disease program selected for a government-funded breakthrough drug development project.

2020

Initiated Phase 2 clinical trial of NuGel for atopic dermatitis.
Completed Phase 1 trial of NuSepin for sepsis.
Initiated Phase 2 clinical trial of NuSepin for COVID-19.
Selected by the Ministry of Trade, Industry and Energy for a national project on nanobody-based therapeutics and diagnostics using the NanoMab platform.

2021

Signed MOU with Cellbion Co. for joint development of cancer therapeutics.
Received the First-in-Class Award at the 2021 Korea Industry Awards.
Signed licensing-out (L/O) agreement with Kukjeon Pharmaceutical for Alzheimer’s treatment.
Signed MOU with Dong-A ST for joint development of NanoMab-based biopharmaceuticals.
Signed MOU with the Korea Research Institute of Bioscience and Biotechnology (KRIBB) for NanoMab research collaboration.

2022

NuSepin (COVID-19 treatment) selected by KDDF for national clinical support program.
Received IND approval for global Phase 2b/3 clinical trial of NuSepin.
Signed licensing-out (L/O) agreement with Bridge Biotherapeutics for idiopathic pulmonary fibrosis treatment.
Signed MOU with DongKook Pharmaceutical for joint research on inflammatory disease treatments.
Listed on the KOSDAQ market.
Received the 2022 Korea Innovation Company Award.
Received the First-in-Class Award at the Korea Industry Awards for the second consecutive year.

2023

Established U.S. subsidiary, Hudson Therapeutics Inc.
Completed global Phase 2b clinical trial of NuSepin (COVID-19 treatment).
Received IND approval from FDA and MFDS for Phase 2b trial of NuGel (atopic dermatitis).
Received the First-in-Class Award at the 2023 Korea Industry Awards (third consecutive year).
Received the Bio New Drug Grand Prize at the 2023 National Industry Awards.

2024

Signed MOU with Korea University for joint development of treatment for respiratory failure.
Signed MOU with DongKook Pharmaceutical for development of anti-inflammaging skincare products.
Received the 2024 Korea Innovation Company Award.
Received the K-First-in-Class Award in the Immunology-based Drug category at the 10th Korea Industry Awards (fourth consecutive year).
Received the National Industry Grand Prize in the Bio New Drug category (second consecutive year).
Inducted into the Korea CEO Hall of Fame (third consecutive year).
Received the K-ESG Management Innovation Grand Prize (Social Sector) from the National Assembly’s Industry, Trade, and SMEs Committee.

2025

Completed Part 1 and initiated Part 2 of the U.S. Phase 2b clinical trial of NuGel (atopic dermatitis treatment).

Immunology